Prognostic value of p27(Kip1) and cyclinD1 expression in esophageal cancer

Oncology

Volumn 57, Issue 4, 1999, Pages 311-317

  Itami, Atsushi ^a   Shimada, Yutaka ^a   Watanabe, Go ^a   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CyclinD1; Esophageal cancer; Kip1; p27; Prognostic factor; Survival

Indexed keywords

CYCLIN D1; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; ESOPHAGUS CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

EID: 0032745862     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012067     Document Type: Article

References (47)

1. Raff MC: Size control: The regulation of cell number in animal development. Cell 1996;86: 173-175.
2. Sherr CJ, Roberts JM: Inhibition of mammalian G1 cyclin-dependent kinase. Genes Dev 1995;9:1149-1163.
3. Sherr CJ: G1 phase progression: Cycling on cue. Cell 1994;79:551-555.
4. Quelle DE, Ashmun RA, Shurtleff SA, Kato J, Bar-Sagi D, Roussel MF, Sheer CJ: Overexpression of mouse D-type cyclins accelerate G1 phase in rodent fibroblasts. Genes Dev 1993;7: 1559-1571.
5. Hunter T, Pines J: Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
6. Hall M, Peters G: Genetic alteration of cyclin, cyclin dependent kinase, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
7. Weinstein IB, Zhou P: Cell Cycle Control Gene Defects and Human Cancer. Encyclopedia of Cancer. New York, Academic Press, 1996, pp 250-267.
8. Jiang W, Zhang YJ, Kahn SM, Hollestein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026-9030.
9. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-1817.
10. Bartkava J, Lukas J, Strauss N, Bartek J: The PRAD-1/Cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-573.
11. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-674.
12. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M: Altered P16/MTS1/CDKN2 and cyclinD1/RPAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-2236.
13. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M: CyclinD1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 1996;2:1155-1161.
14. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hatroru T: Overexpression and localization of cyclinD1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-1169.
15. MacLahlan TK, Sang N, Giordano A: Cyclins, cyclin-dependent kinases and Cdk inhibitors: Implication in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127-156.
16. Serran M, Hannon GJ, Beach DA: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
17. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-261.
18. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes Dev 1994;8:2939-2952.
19. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ: Novel INK4 protein, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-2681.
20. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin dependent kinase 4 inhibitor p16/INK4. Cancer Res 1994;54:5816-5820.
21. Haper JW, Admmi GR, Wei N, Keyomarsi K, Elledge SJ: The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-816.
22. Toyoshima H, Hunter T: P27, novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
23. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
24. Sheer CJ: D-type cyclins. Trends Biochem Sci 1995;20:187-190.
25. Elledge SJ, Harper JW: Cdk inhibitors: On the threshold of checkpoints and development. Curr Opin Cell Biol 1994;6:847-852.
26. Kip1, a cyclin-dependent kinase inhibitor, links transforming growth factor-β and contact inhibition to cell cycle. Genes Dev 1994;8:9-22.
27. Kip1, a cyclin-dependent kinase and a potent mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
28. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-573.
29. Kip1 accumulation during the cell cycle. Science 1996;271:1861-1864.
30. Pagano M, Beer-Pomero P, Glass S, Tam SW, Theodoras A, Rolfe M, Draetta G: Targeting ubiquitin-mediated degradation for proliferation inhibitors; in Mihich E, Gousman D (eds): Cancer Genes. New York, Plenum, 1997, pp 255-268.
31. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup HM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3.231-234.
32. Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 1997; 3:227-230.
33. Kip1 and cyclinE, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225.
34. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385.
35. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Balde F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57: 3381-3385.
36. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-629.
37. Mori M, Mimori K, Shiraishi T, Tanaka S, Uedo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nat Med 1997;3: 593.
38. Imamura M, Shimada Y, Kanda Y, et al: Hemodynamic changes after resection of thoracic duct for en bloc resection of esophageal cancer. Jpn J Surg 1992;22:226-232.
39. Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998;79:439-443.
40. Pagano M, Tam SW, Theodoras A, Romero-Beer P, Del Sal G, Chau V, Yew R, Draetta G, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-685.
41. Shibagaki I, Shimada Y, Wagata T, Ikenaga M, Imamura M, Isihzaki K: Allelic analysis of esophageal squamous cell carcinoma. Cancer Res 1994;54:2996-3000.
42. Kip1 displaying body size, multiple organ hyperplasia, and pituitary tumors. Cell 1996;85:707-720.
43. Kip1. Cell 1996;85:721-732.
44. Kip1-deficient mice. Cell 1996; 85:733-744.
45. kip1 protein in human esophageal cancer cell lines that overexpress cyclinD1. Carcinogenesis 1997; 18:1139-1148.
46. Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S: CyclinD1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer 1998;77:92-97.
47. MST1 gene status in human esophageal carcinoma cell line. J Exp Ther Oncol 1996;1:1-12.